Video Length: 00:36:10

 

We sat down with Joel Fruendt, CEO of SenesTech (SNES), to dive into their game-changing fertility control solution for rats — and the massive opportunity unfolding across the U.S. and internationally.

Key Topics Covered: 

• Active pilot deployments in New York City, Los Angeles, Chicago, Boston, San Francisco, Baltimore 
• Global expansion into Indonesia, India, Netherlands and future EU plans 
• How SNES could scale from ~$500K/quarter to multi-million-dollar contracts 
• Timeline for profitability, pilot expansions, and key upcoming catalysts
• Inside their new production facility in Arizona with scalable capacity
• Why one big citywide contract could flip SNES to profitability — and potentially send the stock soaring
• Joel also discusses revenue run-rate targets, the inflection point ahead, and how their proprietary Evolve product is seeing widespread adoption from cities banning poisons. 

Watch until the end for investor Q&A on timelines, red tape, and the likelihood of full-city rollouts by year-end.
If you're a microcap investor looking for the next big inflection, this is an interview you don't want to miss.

Related Articles:
SenesTech Remains Undervalued With Increasing Revenues And Global Product Distribution
SenesTech's Big Play On Small Pests
SenesTech: A Little-Known Biotech Company Worthy Of Attention

More By This Author:
SenesTech CEO Reveals Surprise San Francisco Expansion
SenesTech CEO Interview: Breaking Down Record Earnings & The Road To Profitability
Stock Market Outlook: Key Levels, Short Squeeze Plays And Trade Setups